Table II.

Experimental protocol for in vivo study

Group	Treatment
NOR	Untreated group
PLC	treated with intraperitoneal pilocarpine (100 μg/μl)
OXC SUS	treated with oral Oxcarbazepine suspension (0.5 μg/μl) ¥
OXC GEL	treated with intranasal Oxcarbazepine gel (5 μg/μl) ¥
OXC- NP	treated with intranasal Oxcarbazepine-chitosan nanoparticles in gel (5 μg/μl) ¥

¥ all oxcarbazepine preparations were administered 1 hour before pilocarpine injection. Pilocarpine dose = 380 mg/kg, while oxcarbazepine preparations dose = 0.8 mg/kg. Intranasal solutions were administered in one nostril using micropipette while held in upright position.